PTSD - Post Traumatic Stress DisorderNCT06957210
Post-Traumatic Growth Following Eye Movement Desensitization and Reprocessing Therapy Versus SSRIs in Patients With Post-Traumatic Stress Disorder
A study testing EMDR and SSRIs in people with PTSD - Post Traumatic Stress Disorder, run by Asad Ullah Jan at 2 sites in Pakistan.
Trial summary
This randomized controlled trial investigates the comparative effectiveness of Eye Movement Desensitization and Reprocessing (EMDR) therapy and selective serotonin reuptake inhibitors (SSRIs) in fostering post-traumatic growth among patients diagnosed with post-traumatic stress disorder (PTSD). Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- PTSD - Post Traumatic Stress Disorder
- What is being tested?
- EMDR and SSRIs
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 130 participants
- Where
- 2 sitesPakistan
- Study dates
- 6 May 2025to 31 Dec 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Clinical diagnosis of Post-Traumatic Stress Disorder (PTSD) based on DSM-5 criteria
- Willingness to participate and provide informed consent
- Ability to comply with study procedures
Who cannot join
- Current diagnosis of psychotic disorder, bipolar disorder, or severe major depressive episode with psychotic features
- Active substance use disorder within the past 6 months
- Severe cognitive impairment or inability to complete study assessments
Trial locations and contacts
2 sites in 1 country.
Pakistan2 sites
Combined Military Hospital
Nowshera, KPK, 25770
Department of Psychiatry, Combined Military Hospital Nowshera
Nowshera, KPK, 25770
About this study
Official title: Post-Traumatic Growth Following Eye Movement Desensitization and Reprocessing Therapy Versus SSRIs in Patients With Post-Traumatic Stress Disorder: A Randomized Controlled Trial
This randomized controlled trial investigates the comparative effectiveness of Eye Movement Desensitization and Reprocessing (EMDR) therapy and selective serotonin reuptake inhibitors (SSRIs) in fostering post-traumatic growth among patients diagnosed with post-traumatic stress disorder (PTSD). Participants will be randomized to receive either EMDR therapy or standard SSRI pharmacotherapy. The primary objective is to evaluate the extent of psychological growth and recovery achieved through each intervention, aiming to guide future therapeutic strategies for PTSD.
- Conditions
- PTSD - Post Traumatic Stress Disorder
- Being tested
- EMDR, SSRIs
- Keywords
- PTSD, Post-traumatic Stress Disorder, Post-traumatic Growth, EMDR, Eye Movement Desensitization and Reprocessing
- Medical subject headings
- Combat Disorders, Stress Disorders, Post-Traumatic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EMDRBehavioural
Participants will receive structured EMDR therapy sessions conducted by trained therapists following standard EMDR protocols. Sessions will occur weekly over a 6 week period.
SSRIsDrug
Participants will receive pharmacotherapy with an SSRI prescribed according to standard clinical guidelines for PTSD, monitored by a psychiatrist over a 6-week period.
| Study group | Role | What they receive |
|---|---|---|
| EMDR | Experimental | EMDR therapy Receives: Behavioral: EMDR |
| SSRIs | Active comparator | Acting as control group Receives: Drug: SSRIs |
What is being measured
The primary outcome is the main question the study is designed to answer.
Post-Traumatic Growth (PTG) measured by Post-Traumatic Growth Inventory (PTGI)
Change in PTGI total score from baseline to 6 weeks.
Measured: 6 weeks
Secondary outcomes (1)
PTSD symptom severity measured by PTSD Checklist
Change in PTSD Checklist total score from baseline to 6 weeks.
Measured: 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 May 2025
- Study start6 May 2025
- Primary completion30 Nov 2025
- Study completion31 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PTSD - Post Traumatic Stress DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 130 participants (actual)
Sponsor and investigators
- Lead sponsor
- Asad Ullah Jan
- Sponsor type
- Other government
- Responsible party
- Sponsor-investigator, Asad Ullah Jan, Combined Military Hospital Nowshera
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06957210
- Sponsor's protocol ID
- CMHNSR-REF-15
- Status last verified
- May 2026
- First submitted
- 26 Apr 2025
- Last updated
- 7 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Privacy concerns and confidentiality protections for participants limit the feasibility of public data sharing.
Study at a glance
From the registry record, last updated by the sponsor on 7 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Post-Traumatic Growth Following Eye Movement Desensitization and Reprocessing Therapy Versus SSRIs in Patients With Post-Traumatic Stress Disorder: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT06957210
- Acronym / sponsor ID
- CMHNSR-REF-15
- Conditions
- PTSD - Post Traumatic Stress Disorder
- Keywords
- PTSD, Post-traumatic Stress Disorder, Post-traumatic Growth, EMDR, Eye Movement Desensitization and Reprocessing
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 130 participants (actual)
- Lead sponsor
- Asad Ullah JanOther government
- Study start
- 6 May 2025 (actual)
- Primary completion
- 30 Nov 2025 (actual)
- Study completion
- 31 Dec 2025 (actual)
- First posted
- 4 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized controlled trial investigates the comparative effectiveness of Eye Movement Desensitization and Reprocessing (EMDR) therapy and selective serotonin reuptake inhibitors (SSRIs) in fostering post-traumatic growth among patients diagnosed with post-traumatic stress disorder (PTSD). Participants will be randomized to receive either EMDR therapy or standard SSRI pharmacotherapy. The primary objective is to evaluate the extent of psychological growth and recovery achieved through each intervention, aiming to guide future therapeutic strategies for PTSD.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| EMDR | Experimental | Behavioral: EMDREMDR therapy |
| SSRIs | Active comparator | Drug: SSRIsActing as control group |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Clinical diagnosis of Post-Traumatic Stress Disorder (PTSD) based on DSM-5 criteria
- Willingness to participate and provide informed consent
- Ability to comply with study procedures
Key exclusion criteria (3 listed)
- Current diagnosis of psychotic disorder, bipolar disorder, or severe major depressive episode with psychotic features
- Active substance use disorder within the past 6 months
- Severe cognitive impairment or inability to complete study assessments
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EMDRParticipants will receive structured EMDR therapy sessions conducted by trained therapists following standard EMDR protocols. Sessions will occur weekly over a 6 week period. | Behavioural | EMDR |
| SSRIsParticipants will receive pharmacotherapy with an SSRI prescribed according to standard clinical guidelines for PTSD, monitored by a psychiatrist over a 6-week period. | Drug | SSRIs |
Primary outcome
Post-Traumatic Growth (PTG) measured by Post-Traumatic Growth Inventory (PTGI)
Time frame: 6 weeks
Change in PTGI total score from baseline to 6 weeks.
1 secondary outcome
PTSD symptom severity measured by PTSD Checklist
Time frame: 6 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 May 2026.
- Individual participant dataSharing planned: No. Privacy concerns and confidentiality protections for participants limit the feasibility of public data sharing.
Related trials for PTSD - Post Traumatic Stress Disorder
Not yet recruiting
The Development of a Transdiagnostic Intervention to Improve Social Functioning and Intimate Relationships Among Veterans
Alcohol Problems, Post-Traumatic Stress Disorder
RecruitingPhase 3
An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD
Post Traumatic Stress Disorder
Active, not recruitingObservational study
Trauma-Related Attributions in Trauma Treatment: An Observational Study
PTSD
Not yet recruitingPhase 2
Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies
PTSD, PTSD - Post Traumatic Stress Disorder
RecruitingPhase 1
Open-Label Psilocybin Study in Transdiagnostic Population
Transdiagnostic, Depression - Major Depressive Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing EMDR and SSRIs in people with PTSD - Post Traumatic Stress Disorder, run by Asad Ullah Jan at 2 sites in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Post-Traumatic Growth (PTG) measured by Post-Traumatic Growth Inventory (PTGI) (time frame: 6 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 May 2026.